Abstract
As regulatory obstacles to biosimilars development have become increasingly
resolved, a growing number of opportunities have been created for generics
companies in the biopharmaceutical market, which is forecast to value in
excess of $135 billion by 2011. In response, the originators of
biopharmaceutical products are resorting to a range of defensive tactics,
including the reformulation of existing products to improve efficacy, the
implementation of more efficient delivery systems and the pursuit of
intellectual property battles. ' Negotiating the Emerging Biosimilars
Landscape' is a new report published by Business Insights that examines the
structure of the biopharmaceutical industry and the strategic approaches taken
to alleviate the threat posed by the biosimilar market. The key factors
affecting market access within the biosimilars market are assessed and the
latest issues surrounding bioequivalence are examined. This report also
provides a comprehensive review of the current legislative and regulatory
positions of key geographic regions in addition to evaluating their
anticipated future legislative changes and outcomes.
| 
View Cart
